Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Eur J Med Chem
2020 Nov 01;205:112669. doi: 10.1016/j.ejmech.2020.112669.
Show Gene links
Show Anatomy links
Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation.
Pismataro MC, Horenstein NA, Stokes C, Quadri M, De Amici M, Papke RL, Dallanoce C.
???displayArticle.abstract???
The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure-activity relationship investigation of the archetypal silent agonist NS6740 (1,4-diazabicyclo[3.2.2]nonan-4-yl(5-(3-(trifluoromethyl)-phenyl)-furan-2-yl)methanone) (1) to elucidate the ligand-receptor interactions responsible for the α7 silent activation. In this study, NS6740 fragments 11-16 and analogs 17-32 were designed, synthesized, and assayed on human α7 nAChRs expressed in Xenopus laevis oocytes with two-electrode voltage clamping experiments. All together the structural portions of NS6740 were critical to engender its peculiar activity profile. The diazabicyclic nucleus was essential but not sufficient for inducing α7 silent activation. The central hydrogen-bond acceptor core and the aromatic moiety were crucial for promoting prolonged α7 receptor binding and sustained desensitization. Compounds 13 and 17 were efficacious partial agonists. Compounds 12, 21, 23-26, and 30 strongly desensitized α7 nAChR and therefore may be of interest for additional investigation of inflammation responses. We gained key structural information useful for further silent agonist development.
???displayArticle.pubmedLink???
32810771 ???displayArticle.pmcLink???PMC7590973 ???displayArticle.link???Eur J Med Chem ???displayArticle.grants???[+]
Báez-Pagán,
Activation of the Macrophage α7 Nicotinic Acetylcholine Receptor and Control of Inflammation.
2015, Pubmed
Báez-Pagán,
Activation of the Macrophage α7 Nicotinic Acetylcholine Receptor and Control of Inflammation.
2015,
Pubmed Bressy,
A route to annulated indoles via a palladium-catalyzed tandem alkylation/direct arylation reaction.
2005,
Pubmed Briggs,
Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
2009,
Pubmed
,
Xenbase Chojnacka,
Synthesis and evaluation of a conditionally-silent agonist for the α7 nicotinic acetylcholine receptor.
2013,
Pubmed
,
Xenbase Clark,
Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.
2014,
Pubmed Colón-Sáez,
A mutation in the extracellular domain of the α7 nAChR reduces calcium permeability.
2014,
Pubmed Corradi,
Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery.
2016,
Pubmed Couturier,
A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX.
1990,
Pubmed
,
Xenbase Dallanoce,
New spirocyclic Δ²-isoxazoline derivatives related to selective agonists of α7 neuronal nicotinic acetylcholine receptors.
2011,
Pubmed Dallanoce,
Investigating the hydrogen-bond acceptor site of the nicotinic pharmacophore model: a computational and experimental study using epibatidine-related molecular probes.
2013,
Pubmed Dallanoce,
Synthesis and binding affinity at α4β2 and α7 nicotinic acetylcholine receptors of new analogs of epibatidine and epiboxidine containing the 7-azabicyclo[2.2.1]hept-2-ene ring system.
2012,
Pubmed Dallanoce,
Design, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Δ2-isoxazoline derivatives as potent and selective agonists of α7 nicotinic acetylcholine receptors.
2011,
Pubmed de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed Di Cesare Mannelli,
Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation.
2014,
Pubmed Fujii,
Expression and Function of the Cholinergic System in Immune Cells.
2017,
Pubmed Gotti,
Neuronal nicotinic receptors: from structure to pathology.
2004,
Pubmed Grazioso,
Design of novel alpha7-subtype-preferring nicotinic acetylcholine receptor agonists: application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies.
2009,
Pubmed Gulsevin,
Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site.
2019,
Pubmed
,
Xenbase Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase Horenstein,
Anti-inflammatory Silent Agonists.
2017,
Pubmed Kabbani,
Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.
2018,
Pubmed King,
A G protein-coupled α7 nicotinic receptor regulates signaling and TNF-α release in microglia.
2017,
Pubmed King,
Identification and Characterization of a G Protein-binding Cluster in α7 Nicotinic Acetylcholine Receptors.
2015,
Pubmed Lee,
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
2005,
Pubmed Lendvai,
α7 nicotinic acetylcholine receptors and their role in cognition.
2013,
Pubmed Matera,
In vivo and in vitro ADMET profiling and in vivo pharmacodynamic investigations of a selective α7 nicotinic acetylcholine receptor agonist with a spirocyclic Δ2-isoxazoline molecular skeleton.
2018,
Pubmed Matera,
Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the α3β4 nicotinic acetylcholine receptor subtype.
2016,
Pubmed Nordman,
Microtubule dynamics at the growth cone are mediated by α7 nicotinic receptor activation of a Gαq and IP3 receptor pathway.
2014,
Pubmed Papke,
The minimal pharmacophore for silent agonism of the α7 nicotinic acetylcholine receptor.
2014,
Pubmed
,
Xenbase Papke,
Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.
2018,
Pubmed
,
Xenbase Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor.
2015,
Pubmed
,
Xenbase Papke,
Merging old and new perspectives on nicotinic acetylcholine receptors.
2014,
Pubmed Paulo,
Proteomic analysis of an alpha7 nicotinic acetylcholine receptor interactome.
2009,
Pubmed Pesti,
Kinetic properties and open probability of α7 nicotinic acetylcholine receptors.
2014,
Pubmed Quadri,
Sulfonium as a Surrogate for Ammonium: A New α7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity.
2017,
Pubmed
,
Xenbase Quadri,
Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation.
2017,
Pubmed
,
Xenbase Quadri,
The Antinociceptive and Anti-Inflammatory Properties of the α7 nAChR Weak Partial Agonist p-CF3 N,N-diethyl-N'-phenylpiperazine.
2018,
Pubmed
,
Xenbase Quadri,
Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the α7 nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation.
2018,
Pubmed Quadri,
Dissection of N,N-diethyl-N'-phenylpiperazines as α7 nicotinic receptor silent agonists.
2016,
Pubmed
,
Xenbase Rosas-Ballina,
The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE.
2009,
Pubmed Scabia,
ICH3, a selective alpha7 nicotinic acetylcholine receptor agonist, modulates adipocyte inflammation associated with obesity.
2020,
Pubmed Séguéla,
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
1993,
Pubmed
,
Xenbase Stokes,
Looking below the surface of nicotinic acetylcholine receptors.
2015,
Pubmed Thomsen,
The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
2012,
Pubmed Tracey,
Physiology and immunology of the cholinergic antiinflammatory pathway.
2007,
Pubmed Treinin,
Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway.
2017,
Pubmed Williams,
Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.
2012,
Pubmed
,
Xenbase Williams,
Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.
2011,
Pubmed
,
Xenbase Zhong,
Nicotine elicits prolonged calcium signaling along ventral hippocampal axons.
2013,
Pubmed
